DSPE-PEG2000 磷脂：提升锰锌铁氧体纳米晶生物稳定性与体内富集

一、文献内DSPE-PEG2000、DSPE-PEG2000-FITC核心作用

1. DSPE-PEG2000

作为纳米晶表面PEG化修饰磷脂，用于锰锌铁氧体纳米晶的表面改性。DSPE的疏水端锚定在磁性纳米晶表面，亲水PEG2000链向外伸展，构建水化层。

– 降低磁性纳米颗粒的表面能，抑制颗粒之间的团聚，提升纳米晶在水相、细胞培养基中的胶体稳定性；

– 减少血清蛋白非特异性吸附，降低网状内皮系统的清除效应，改善纳米颗粒生物相容性；

– 为纳米晶提供长循环特性，保障在tumor区域富集，配合瘤内植入微磁铁实现磁场富集，进而诱导铁死亡与免疫原性细胞死亡，协同Treatment 前列腺Cancer。

2. DSPE-PEG2000-FITC

同骨架磷脂PEG衍生物，带有FITC荧光基团，主要用于标记示踪。

– 采用与DSPE-PEG2000共修饰策略，将FITC荧光探针引入锰锌铁氧体纳米晶表面；

– 借助荧光信号，在体外细胞实验中直观观测纳米颗粒的细胞摄取、胞内分布，验证磁性纳米晶进入前列腺Cancer细胞的效率，用于定性、半定量细胞成像分析；

– 不干扰PEG水化层结构，保留纳米颗粒原有分散稳定性，实现“纳米载体+荧光示踪”一体化。

二、该文献材料体系简介

该研究制备PEG修饰锰锌铁氧体磁性纳米晶，结合瘤内植入微磁铁的局部磁场富集策略。磁性纳米晶在tumor部位富集后，可触发tumor细胞铁死亡，同时诱导免疫原性细胞死亡，释放损伤相关分子模式，激活机体抗tumor免疫，实现铁死亡联合免疫协同前列腺CancerTreatment 。DSPE-PEG系列磷脂是构建该磁性纳米诊疗剂的关键表面修饰材料。

三、产品应用价值

DSPE-PEG2000是脂质、无机纳米颗粒（磁性氧化铁、铁氧体、金纳米粒等）较常用的PEG化磷脂修饰试剂，用于改善纳米材料水溶性、稳定性与体内长循环效果；DSPE-PEG2000-FITC为荧光标记型磷脂，可直接共掺用于纳米载体荧光标记、细胞摄取示踪、体外荧光成像，广泛应用于磁性纳米诊疗、铁死亡、免疫Treatment 相关纳米药物体系构建。

四、相关产品与服务介绍

现货供应DSPE-PEG2000、DSPE-PEG2000-FITC等多种DSPE-PEG衍生物，同时提供不同分子量、不同荧光基团（Cy系列、ICG等）修饰的磷脂PEG产品；支持磁性纳米晶、脂质纳米载体的表面PEG修饰定制，可完成材料DLS、Zeta电位、TEM、荧光光谱等表征，承接纳米载体制备、体外细胞成像评价等CDMO研发服务，助力铁死亡、tumor免疫方向科研项目。

文献：PEGylated Manganese–Zinc Ferrite Nanocrystals Combined with Intratumoral Implantation of Micromagnets Enabled Synergetic Prostate Cancer Therapy via Ferroptotic and Immunogenic Cell Death

文献链接：https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.202207077

作者：Hui Wang, Yu Guan, Chun Li, Jia Chen, Shaoyu Yue, Jieying Qian, Bangshun Dai, Changqin Jiang, Chenghao Wen, Longping Wen, Chaozhao Liang, Yunjiao Zhang, Li Zhang

相关产品：DSPE-PEG 2000、DSPE-PEG2000 -FITC

原文摘要：

Therapeutic efficacy for prostate cancer is highly restricted by insufficient drug accumulation and the resistance to apoptosis and immunogenic cell death (ICD). Although enhanced permeability and retention (EPR) effect of magnetic nanomaterials could benefit from external magnetic field, it falls off rapidly with increased distance from magnet surface. Considering the deep location of prostate in pelvis, the improvement of EPR effect by external magnetic field is limited. In addition, apoptosis resistance and cGAS-STING pathway inhibition-related immunotherapy resistance are major obstacles to conventional therapy. Herein, the magnetic PEGylated manganese-zinc ferrite nanocrystals (PMZFNs) are designed. Instead of providing external magnet, micromagnets into tumor tissues are intratumorally implanted to actively attract and retain intravenously-injected PMZFNs. As a result, PMZFNs accumulate in prostate cancer with high efficacy, depending on the established internal magnetic field, which subsequently elicit potent ferroptosis and the activation of cGAS-STING pathway. Ferroptosis not only directly suppresses prostate cancer but also triggers burst release of cancer-associated antigens and consequently initiates ICD against prostate cancer, where activated cGAS-STING pathway further amplifies the efficacy of ICD by generating interferon-β. Collectively, the intratumorally implanted micromagnets confer a durable EPR effect of PMZFNs, which eventually achieve the synergetic tumoricidal efficacy with negligible systemic toxicity.